Please login to the form below

Not currently logged in
Email:
Password:

lung disease

This page shows the latest lung disease news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

NICE recommends Amgen’s Lumykras for non-small-cell lung cancer

It will be available as an option for adult patients diagnosed with the KRAS G12C mutation-positive locally advanced, or metastatic non-small-cell lung cancer (NSCLC) patients, whose disease has ... lung cancers and approximately 13% of these are

Latest news

More from news
Approximately 4 fully matching, plus 124 partially matching documents found.

Latest Intelligence

  • Addressing the payer-regulator evidence gap in early-stage cancer Addressing the payer-regulator evidence gap in early-stage cancer

    complications of disease whether measured symptomatically, radiographically, and increasingly with novel measurement techniques. ... endpoints that can better characterise the benefit of new drugs for early disease.

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    The lexicon of lung disease has been developing over four centuries from its early livid descriptions such as turgid, voluminous and catarrh coined by physicians navigating various airflow restrictions now known ... COPD was a Cinderella disease when I

  • #OrkambiNow? #OrkambiNow?

    People with this genetically inherited disease are vulnerable to potentially deadly lung infections, and currently half the people in the UK with CF die before the age of 31. ... died from the disease who might have lived had they received the drug.

  • Significant figures Significant figures

    ALIS (Amikacin liposome inhalation suspension) is being developed as a treatment for refractory non tuberculous Mycobacterial (NTM) lung disease, a rare progressive, destructive infection caused by mycobacterium avium complex. ... However, Insmed

  • Pharma deals during August 2014 Pharma deals during August 2014

    lung scarring condition for which there are no approved drugs in the US. ... It also has potential utility in treating systemic sclerosis-related Interstitial Lung Disease.

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....